Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7447.09 | 0.9620 | 0.9518 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7447.09 | 0.8626 | 0.8220 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7447.09 | 0.5848 | 0.4261 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7447.09 | 0.0075 | -0.9087 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7447.09 | 0.0039 | -0.9395 | 1.5863 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7449.091 | 1.0161 | 1.0177 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7449.091 | 0.9848 | 0.9833 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7449.091 | 0.9719 | 0.9688 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7449.091 | 1.0010 | 1.0012 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7449.091 | 1.0729 | 1.0791 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7449.091 | 0.9042 | 0.8921 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7449.091 | 0.5788 | 0.4799 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7449.091 | 0.0138 | -0.8107 | 1.8158 | |
| HCC1569 | HER2amp | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7449.091 | 0.0012 | -0.9499 | 1.8158 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7450.091 | 1.4898 | 1.9322 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7450.091 | 2.8858 | 4.5306 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7450.091 | 2.7673 | 4.3125 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7450.091 | 0.2825 | -0.4055 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7450.091 | 2.8027 | 4.3776 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7450.091 | 1.0043 | 1.0083 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7450.091 | 1.7957 | 2.5078 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7450.091 | 0.0384 | -0.9123 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7450.091 | 0.0308 | -0.9291 | 1.0419 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7451.091 | 0.9373 | 0.9405 | 2.1415 | |
| HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7451.091 | 0.9560 | 0.9584 | 2.1415 |